Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

Joost W Geenen; Ekaterina V Baranova; Folkert W Asselbergs; Anthonius de Boer; Rick A Vreman; Colin Na Palmer; Anke H. Maitland-van der Zee; Anke M Hövels

doi:10.2217/pgs-2017-0063

Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

Joost W Geenen, Ekaterina V Baranova, Folkert W Asselbergs, Anthonius de Boer, Rick A Vreman, Colin Na Palmer, Anke H. Maitland-van der Zee, Anke M Hövels

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

AIM: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.

MATERIALS & METHODS: A decision tree was used.

RESULTS: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.

CONCLUSION: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.

Original language	English
Pages (from-to)	1143-1153
Number of pages	11
Journal	Pharmacogenomics
Volume	18
Issue number	12
DOIs	https://doi.org/10.2217/pgs-2017-0063
Publication status	Published - Aug 2017

Keywords

ACE inhibitor induced angioedema
ACE inhibitors
adverse drug reactions
angioedema
cardiovascular drugs
cost-effectiveness
health technology assessment
pharmacogenomic test

Access to Document

10.2217/pgs-2017-0063

Cite this

@article{e7cec035d85345fdb02613daf3d260da,

title = "Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs",

abstract = "AIM: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.MATERIALS \& METHODS: A decision tree was used.RESULTS: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100\% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.CONCLUSION: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.",

keywords = "ACE inhibitor induced angioedema, ACE inhibitors, adverse drug reactions, angioedema, cardiovascular drugs, cost-effectiveness, health technology assessment, pharmacogenomic test",

author = "Geenen, \{Joost W\} and Baranova, \{Ekaterina V\} and Asselbergs, \{Folkert W\} and \{de Boer\}, Anthonius and Vreman, \{Rick A\} and Palmer, \{Colin Na\} and \{Maitland-van der Zee\}, \{Anke H.\} and H{\"o}vels, \{Anke M\}",

note = "Publisher Copyright: {\textcopyright} 2017 2017 Future Medicine Ltd.",

year = "2017",

month = aug,

doi = "10.2217/pgs-2017-0063",

language = "English",

volume = "18",

pages = "1143--1153",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis Ltd.",

number = "12",

}

TY - JOUR

T1 - Early health technology assessments in pharmacogenomics

T2 - a case example in cardiovascular drugs

AU - Geenen, Joost W

AU - Baranova, Ekaterina V

AU - Asselbergs, Folkert W

AU - de Boer, Anthonius

AU - Vreman, Rick A

AU - Palmer, Colin Na

AU - Maitland-van der Zee, Anke H.

AU - Hövels, Anke M

PY - 2017/8

Y1 - 2017/8

N2 - AIM: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.MATERIALS & METHODS: A decision tree was used.RESULTS: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.CONCLUSION: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.

AB - AIM: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.MATERIALS & METHODS: A decision tree was used.RESULTS: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.CONCLUSION: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.

KW - ACE inhibitor induced angioedema

KW - ACE inhibitors

KW - adverse drug reactions

KW - angioedema

KW - cardiovascular drugs

KW - cost-effectiveness

KW - health technology assessment

KW - pharmacogenomic test

U2 - 10.2217/pgs-2017-0063

DO - 10.2217/pgs-2017-0063

M3 - Article

C2 - 28745583

SN - 1462-2416

VL - 18

SP - 1143

EP - 1153

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 12

ER -

Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

Abstract

Keywords

Access to Document

Fingerprint

Cite this